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362Objectives: We sought to understand the factors modulating left heart reverse remodeling after aortic valve
replacement, the relationship between the preoperative symptoms and modulators of left heart remodeling,
and their influence on long-term survival.
Methods: From October 1991 to January 2008, 4264 patients underwent primary aortic valve replacement for
aortic stenosis. Changes in the time course of left ventricular reverse remodeling were assessed using 5740 post-
operative transthoracic echocardiograms from 3841 patients.
Results: Left ventricular hypertrophy rapidly declined after surgery, from 137  42 g/m2 preoperatively to
115  27 by 2 years and remained relatively constant but greater than the upper limit of normal. The most im-
portant risk factor for residual left ventricular hypertrophy was greater preoperative left ventricular hypertrophy
(P<.0001). Other factors included a greater left atrial diameter (reflecting diastolic dysfunction), a lower ejec-
tion fraction, and male gender. An increased postoperative transprosthesis gradient was associated with greater
residual left ventricular hypertrophy; however, its effect was minimal. Preoperative severe left ventricular
hypertrophy and left atrial dilatation reduced long-term survival, independent of symptom status.
Conclusions: Severe left ventricular hypertrophy with left atrial dilatation can develop from severe aortic
stenosis, even without symptoms. These changes can persist, are associated with decreased long-term survival
even after successful aortic valve replacement, and could be indications for early aortic valve replacement if
supported by findings from an appropriate prospective study. (J Thorac Cardiovasc Surg 2014;147:362-9)Supplemental material is available online.e Cleveland Clinic Lerner College of Medicine,a Case Western Reserve Uni-
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The Journal of Thoracic and Cardiovascular SurgLong-term survival after aortic valve (AV) replacement
(AVR) for aortic stenosis is strongly related to the timing of
surgery in the natural disease course.1 Left ventricular (LV)
hypertrophy and consequent diastolic dysfunction are impor-
tant consequences of long-standing aortic stenosis that nega-
tively influence postoperative survival.1,2 Despite their
implications, these measures are largely absent from current
symptom-based guidelines for the appropriateness of AVR.3
We hypothesized that LV hypertrophy is not fully revers-
ible after AVR and that the factors influencing remodeling
and its reversal could be used to refine the guidelines for
the optimal timing of AVR in patients with severe aortic ste-
nosis. Therefore, we sought to understand the effect of AVR
and other factors that modulate left heart reverse remodeling,
the relationship between the preoperative symptoms and the
modulators of left heart remodeling, and the influence of the
symptoms and left heart remodeling on long-term survival.METHODS
Patients
From October 1991 to January 2008, 4264 Cleveland Clinic patients
underwent primary AVR with a single type of bioprosthesis for severe aor-
tic stenosis, defined as an aortic valve area less than 1 cm2, with or without
coronary artery bypass grafting (Table 1 and Table E1). Regurgitationery c January 2014
Abbreviations and Acronyms
AV ¼ aortic valve
AVR ¼ AV replacement
LA ¼ left atrial
LV ¼ left ventricular
LVEF ¼ LV ejection fraction
LVMI ¼ LV mass index
TTE ¼ transthoracic echocardiogram
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D(mixed lesion) was acceptable if the aortic valvemet the criterion for severe
aortic stenosis. Patients with predominant aortic regurgitation, infective
endocarditis, rheumatic valve disease, or indications for AVR other than
aortic stenosis, and those who underwent other concurrent valvar or aortic
operations, were excluded.
The preoperative, operative, and postoperative variables were retrieved
from the prospective Cleveland Clinic Cardiovascular Information Regis-
try and the echocardiographic variables from the Echocardiography Data-
base. Both have been approved for research by the institutional review
board, with patient consent waived.
Echocardiography
All preoperative measurements were retrieved from the transthoracic
echocardiogram (TTE) recorded nearest to, but before, the date of AVR
(Table 1). The median interval between the TTE and AVR was 7 days, and
90% of procedures were performedwithin 57 days. The LVmass was calcu-
lated using the formula validated by Devereux and colleagues.4 The peak
instantaneous AV gradients were calculated from the Doppler velocity.
Identical measurements were made on all available postoperative TTEs.
Echocardiograms were routine before hospital discharge, with follow-up
evaluation at the discretion of the referring physician. A total of 8905 post-
operative echocardiogramswere available for 3850patients (90%of thepop-
ulation; Figure E1). The LV mass index (LVMI) was available from 5740
TTEs (2696 patients), the left atrial (LA) diameter from 5787 TTEs (2890
patients), the LVejection fraction (LVEF) from 7506 TTEs (3458 patients),
and the AV peak gradient from 7203 TTEs (3492 patients). This permitted
reliable evaluation of the temporal trend to 10 years. Patientswithout postop-
erative TTEs were included only in the preoperative and survival models.
Follow-up
Patients were systematically followed up for 2 years and then every 5
years by telephone and mailed questionnaires. These follow-up data
were supplemented with Social Security Death Master File data. Follow-
up information was unavailable for 120 patients (2.8%). The median
follow-up period was 5.7 years (mean, 6.1  4.0 years), and 25,878
patient-years of data were available for analysis; 25% of the living patients
were followed up for more than 9 years and 10% for more than 12 years.
Statistical Analysis
Left heart reverse remodeling: Time course. Nonlinear
mixed-model regression analysis was used to characterize the time course
of the postoperative LVMI from the repeated measures data (SAS PROC
NLMIXED; SAS Institute, Cary, NC),5 using a multiphase parametric
model (Appendix E1). This same approach was used to characterize the
time courses of the postoperative LA diameter, LVEF, and peak transpros-
thesis gradient.
Left heart reverse remodeling: Modulators. The preopera-
tive and intraoperative variables (Appendix E2) were screened for an asso-
ciation with the postoperative LVMI, LA diameter, LVEF, and peak
transprosthesis gradient using ordinary multivariate linear regressionThe Journal of Thoracic and Ca(SAS PROC REG). The resulting candidates and their transformations
were simultaneously entered into each temporal phase and then eliminated
individually until all variables remaining had a P value of .1. Thereafter,
to evaluate the possible effect of the time course of the peak transprosthesis
AV gradient on the LVMI, the peak gradient was treated as a time-
dependent covariable (Appendix E3).
For the investigation of preoperative remodeling, because preoperative
variables are importantly related to left heart reverse remodeling, we iden-
tified the correlates of preoperative LVMI, LA diameter, and LVEF using
linear regression analysis. Variable selection was performed using an auto-
mated analysis of 500 bootstrap data sets, with P  .05 for the retention of
variables in the model.6 Variables appearing in 50% or more of the models
were considered in the final model.
Left heart remodeling: Symptoms. The associations between
the New York Heart Association functional class and preoperative LVMI,
LA diameter, and LVEF were determined using Pearson’s correlation coef-
ficient. Comparisons of these variables among the New York Heart Asso-
ciation groups were done using the Kruskal-Wallis nonparametric test.
Left heart remodeling: Survival. Survival was assessed non-
parametrically using the Kaplan-Meier method and parametrically using
a multiphase hazard model that resolved a number of phases of instanta-
neous risk of death (hazard function).7 More information is available at
the following web site: my.clevelandclinic.org/professionals/software/haz-
ard/default.aspx. ‘‘Bagging’’ was used to identify the preoperative and
intraoperative risk factors for death simultaneously for each hazard phase.
To relate the longitudinal LVMI regression to survival, we performed
a focused univariate analysis, followed by a multivariate analysis, using
the preoperative risk factors (Appendix E2) and postoperative LVMI,
with each patient’s postoperative LVMI treated as a time-varying function.
Missing Data
To account for missing values for some covariables, fivefold multiple
imputation was performed8 for all models using a Markov Chain Monte
Carlo technique (SAS PROC MI, version 9.1). Only covariables were
imputed, not the outcomes of interest. Bootstrap bagging for variable selec-
tion, as described, used 1 imputed data set. Regression coefficients and
their variance–covariance matrix for the resulting model were estimated
for each imputed data set. These estimates were combined using the
method of Rubin to obtain the final estimates reported.8
Presentation
Continuous variables are summarized as the mean standard deviation
and as the equivalent 15th, 50th, and 85th percentiles when the values were
skewed. Categorical data are summarized as frequencies and percentages.
All analyses were performed using SAS statistical software (SAS, version
9.1; SAS Institute). Parametric estimates of postoperative echocardio-
graphic measurements, accompanied by asymmetric 68% confidence
limits, comparable to 1 standard error, were obtained using a bootstrap
percentile method.9RESULTS
Left Heart Reverse Remodeling: Time Course
LV hypertrophy, as reflected by the LVMI, declined rapidly
during the first 3 months after AVR, from 137 42 g/m2 pre-
operatively to 115  27 g/m2 by 2 years, and then remained
relatively constant, reaching 119  18 g/m2 by 10 years
(Figure 1). Nevertheless, the LVMI remained greater than
the 95% upper limit of normal (men, 95 g/m2, women, 75 g/
m2).10,11 In contrast, the LA diameter was unchanged
(Figure E2). The LVEF transiently decreased from the preop-
erative values after AVR but recovered to the preoperativerdiovascular Surgery c Volume 147, Number 1 363
TABLE 1. Patient and aortic valve replacement characteristics (total
n ¼ 4264)
Characteristic
Patients with
data available (n) Value
Demographic data
Age (y) 4264 73  9.2
Women 4264 1419 (33)
BSA (m2) 4264 2.0  0.25
Symptoms according to NYHA
functional class
4264
I 630 (15)
II 2330 (55)
III 1007 (24)
IV 297 (7.0)
Aortic valve
Pure aortic stenosis* 4264 2796 (66)
Mixed aortic regurgitation/stenosisy 4264 1468 (34)
Aortic valve stenosis grade 4264
Moderate 238 (5.6)
Moderately severe 360 (8.4)
Severe 3666 (86)
Aortic valve regurgitation grade 4264
None 1521 (36)
Mild 1275 (30)
Moderate 960 (23)
Moderately severe 346 (8.1)
Severe 162 (3.8)
Morphology 4264
Unicuspid 19 (0.45)
Bicuspid 1101 (26)
Tricuspid 3139 (74)
Quadricuspid 5 (0.12)
Orifice area (cm2) 3601 0.69  0.18
Peak gradient (mm Hg) 3722 77  27
Mean gradient (mm Hg) 3714 46  17
Left heart
Left ventricle
Structure
Posterior wall thickness (cm) 3394 1.3  0.23
Intraventricular septal wall
thickness (cm)
3438 1.5  0.28
LVMI (g/m2) 3358 137  42
Geometry
End-diastolic diameter (cm) 3483 4.8  0.82
End-systolic diameter (cm) 3435 3.1  0.93
Function
LV ejection fraction (%) 3351 52  13
Left atrium
LA diameter (cm) 3279 4.3  0.75
Other cardiac comorbidity
Atrial fibrillation or flutter 4264 240 (5.6)
Complete heart block 4264 194 (4.5)
Ventricular arrhythmia 4264 411 (9.6)
Previous cardiac operations (n) 4264
0 3339 (78)
1 925 (22)
(Continued)
TABLE 1. Continued
Characteristic
Patients with
data available (n) Value
Coronary systems diseased (n)z 4218
0 1432 (34)
1 2786 (66)
Noncardiac comorbidity
Documented diagnosis
of hypertension
4212 3101 (74)
Systolic blood pressure (mm Hg) 4251 140  22
Diastolic blood pressure (mm Hg) 4251 73  13
Smoking 4222 2397 (57)
Peripheral arterial disease 4264 2461 (58)
Carotid disease 4264 2331 (55)
Chronic obstructive pulmonary
disease
3548 886 (25)
Diabetes (treated) 4179 912 (22)
Creatinine (mg/dL) 4160 1.2  0.85
Bilirubin (mg/dL) 3583 0.7  0.62
Hematocrit (%) 3734 39  5.3
BSA, Body surface area; NYHA, New York Heart Association; LVMI, left ventricular
mass index; LV, left ventricular; LA, left atrial. *Regurgitation grade mild or less.
yRegurgitation grade moderate or greater. zStenosis 50%.
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Dlevels and remained constant (Figure E3). The transvalvar gra-
dient decreased immediately afterAVRandremainedconstant
to 10 years, averaging 30 mm Hg (Figure 2).Left Heart Reverse Remodeling: Modulators
The factors associated with residual LV hypertrophy, in
decreasing level of importance, included preoperative LV
hypertrophy, LA size, LV systolic dysfunction, and peak
transvalvar gradient.FIGURE 1. Left ventricular (LV) reverse remodeling after aortic valve re-
placement. Solid line represents unadjusted estimate of temporal trend
enclosed within 68% bootstrap percentile confidence limits. Red circles
represent data grouped (without regard to repeated measurements) within
time frames to provide crude verification of model fit. Blacked dashed lines
depict 95% upper limit of normal LVmass index for healthy adult men and
women. Pre-op, Preoperative.
ery c January 2014
FIGURE 2. Relationship between postoperative aortic valve (AV) peak
gradient and postoperative left ventricular (LV)mass index in 2 hypothetical
patients. Each patient had a different AV peak gradient profile, with resul-
tant LV mass index in same color, but otherwise identical patient profiles.
(This is a nomogramof themultivariate equation in Table 2). Values for pre-
operative risk factors set as follows: 74-year-old nondiabetic man with no
renal disease, no right coronary artery disease (stenosis>50%), 3-cm LV
end-systolic diameter, LV ejection fraction of 55%, left atrial diameter of
4.3 cm,AVprosthesis Z-value of0.45, andAVpeak gradient of 74mmHg.
TABLE 2. Risk factors associated with greater postoperative LVMI
Factor Coefficient ± SE
P
value
Overall
Preoperative
Larger LVMI* 0.37  0.027 <.0001
Women 0.54  0.20 .006
Interaction (male 3 [50/age]) 0.29  0.14 .04
Interaction (female 3 [50/age]) 0.74  0.24 .002
Larger LV end-systolic diametery 0.12  0.032 .01
Larger LA diameterz 0.17  0.076 .03
RCA system disease (50% stenosis) 0.086  0.033 .009
Greater systolic blood pressurex 0.26  0.094 .007
Diabetes 0.091  0.040 .02
Renal disease 0.14  0.076 .06
Postoperative
Larger postoperative AV peak gradient{ 0.23  0.031 <.0001
Early phase
Lower LVEFk 0.41  0.078 <.0001
Larger prosthesis Z-value# 0.030  0.016 .06
Late phase
Lower hematocrit** 0.43  0.24 .07
LVMI, Left ventricular mass index; SE, standard error; LV, left ventricular; LA, left
atrial; RCA, right coronary artery; AV, aortic valve; LVEF, left ventricular ejection
fraction. *(LV mass index/125)2, squared transformation. y(LV end-systolic diame-
ter/3)2, squared transformation. z(LA diameter/5)2, squared transformation. x(135/
systolic blood pressure), inverse transformation. {Ln(AV peak gradient/28)2, squared
transformation. kLn(LV ejection fraction), logarithmic transformation. #(Exp
[Z-value/3])2, squared transformation. **(Hematocrit/40)2, squared transformation.
FIGURE 3. Relationship of residual left ventricular (LV) hypertrophy to
degree of preoperative hypertrophy. (This is a nomogram of multivariate
equation in Table 2, solved for 5-year predicted postoperative vs preoper-
ative LVmass index). Values for preoperative risk factors set as in Figure 2,
except for LV mass index of 130 g/m2.
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operative LV hypertrophy was greater preoperative LV
hypertrophy (P< .0001; Table 2 and Figure 3). Patients
with greater preoperative LV hypertrophy tended to have
more severe aortic stenosis, mixed stenosis and regurgita-
tion, a dilated left atrium (Figure 4), and LV systolic dys-
function (Table E2). Patients with severe LV dysfunction,
LA dilatation, and systolic hypertension had more severe
residual postoperative LV hypertrophy (Appendix E4).
Severe preoperative LA dilatation was predictive of
a larger residual LA size after AVR (Table E3). A larger pre-
operative LA size was commonly found in older patients
with more cardiac and noncardiac comorbidities and associ-
ated functional mitral and tricuspid regurgitation (Table E4).
Similar preoperative factors were associated with a larger
left atrium postoperatively.
Patients with lower LV systolic function preoperatively
had a lower LVEF postoperatively (Table E5). Preoperative
LV systolic dysfunction was more common in men with
more severe aortic stenosis and concomitant coronary artery
disease, worse New York Heart Association class, and func-
tional mitral and tricuspid regurgitation (Table E6). Worse
postoperative LV systolic function was found in men with
cardiac comorbidities and low transprosthesis gradients.
Incomplete LV reverse remodeling was associated with
greater postoperative transprosthesis peak gradients. However,
even in patients with greater residual gradients, LV reverse
remodeling was only modestly impaired (Figure 2). A smaller
prosthesis did not impede regression of LV hypertrophy
(Table 2). Patients with greater postoperative transprosthesis
gradientsweremore likely tobeyounger,with smaller prosthe-
ses, greater LVMI, and better LV systolic function (Table E7).The Journal of Thoracic and CaLeft Heart Remodeling: Symptoms
Across awide rangeofLVMIs andLAdiameters, the symp-
toms poorly reflected the degree of LV hypertrophy and dia-
stolic dysfunction (Figure E5), with the distribution of
values broadly overlapping. When the LVMI was 180 g/m2
or greater, 14% of patients were asymptomatic and 50%rdiovascular Surgery c Volume 147, Number 1 365
FIGURE 4. Relationship between preoperative left atrial (LA) diameter
and both preoperative and 5-year postoperative left ventricular (LV) hyper-
trophy. Blue line depicts relationship between preoperative LA diameter
and 5-year postoperative LV mass index. (This is a nomogram of the mul-
tivariate equation in Table 2, as described in Figure 2). Red line depicts
relationship between preoperative LV mass index and preoperative LA
diameter, obtained using nonparametric local regression method.
FIGURE 5. Stratified survival after aortic valve replacement. Each symbol
represents a death, vertical bars represent 68% confidence limits, equiva-
lent to 1 standard error, and numbers in parentheses represent patients
remaining at risk. Solid lines are parametric estimates, and dashed lines
in corresponding color represent survival of an age-race-gender–matched
population. A, Severity of left ventricular (LV) hypertrophy. For clarity,
only patients with extreme values depicted (LV mass index,<96 g/m2 in
15th percentile and180 g/m2 in 85th percentile). B, Left atrial (LA) diam-
eter (<3.55 cm in 15th percentile and 5.0 cm in 85th percentile).
Acquired Cardiovascular Disease Beach et al
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Dmildly symptomatic. When the LA diameter was 5 cm or
greater, 12% of patients were asymptomatic and 47%mildly
symptomatic.
Left Heart Remodeling: Survival
The patients with severe LV hypertrophy (180 g/m2)
had reduced long-term survival compared with the patients
with a LVMI of less than 96 g/m2 at 5 years (73% vs 81%)
and 10 years (45% vs 56%), despite successful AVR
(P ¼ .08; Figure 5, A). Patients with a severely enlarged
left atrium (5.0-cm diameter) had substantially reduced
long-term survival compared to patients with a diameter
of less than 3.55 cm at 5 (61% vs 85%) and 10 (28% vs
62%) years after AVR (P ¼ .006; Figure 5, B). The steep
continuous association of the LA diameter with survival is
demonstrated in Figure 6; only 51% of patients with a diam-
eter of 4 cm were alive 10 years after AVR.
Although greater residual LV hypertrophy was related to
a greater risk of late mortality after AVR (Figure E7 and
Table E8), on multivariate analysis, a greater degree of pre-
operative LV hypertrophy was the more statistically signif-
icant risk factor (Table E9).
DISCUSSION
Principal Findings
AVR in patients with severe aortic stenosis results in
rapid, but incomplete, LV reverse remodeling. Greater
residual LV hypertrophy was present in patients with
more severe preoperative LV hypertrophy, a larger LA
diameter, and worse LV function. A greater postoperative
transprosthesis gradient had a minimal association with re-
sidual LV hypertrophy. The preoperative symptoms were366 The Journal of Thoracic and Cardiovascular Surgnot suggestive of the degree of LV hypertrophy or diastolic
dysfunction; however, both, in particular, the latter, were
associated with decreased long-term survival.LV Reverse Remodeling: Time Course
Although LV hypertrophy declined rapidly after AVR, on
average, it remained greater than the upper limit of normal,
consistent with findings from others.12,13 This suggests that
even successful AVR, in accordancewith current guidelines,
does not result in full recovery of the left ventricle.LV Reverse Remodeling: Modulators
The evaluation of patients with aortic stenosis must
account, not only for changes in valve size and function,
but also the effects of chronicity and severity on the heart.
LV hypertrophy is often considered a benign adaptive
response. However, we, and others, have demonstrated
that the more severe the LV hypertrophy at surgery, the
greater the amount of residual LV hypertrophy afterery c January 2014
FIGURE 6. Non–risk-adjusted relationships of left atrial (LA) diameter to
10-year survival after aortic valve replacement. Parametric estimate
enclosed within 68% confidence band.
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DAVR.12,13 The factors associated with greater preoperative
LV hypertrophy, such as a smaller AV orifice area and
severely calcified leaflets, result in increased gradients
and associated regurgitation. Therefore, defining aortic
stenosis severity should include factors other than the AV
orifice area, jet velocity, and mean gradient.3
LV hypertrophy from long-standing aortic stenosis
results in decreased ventricular compliance and ischemia-
induced myocardial fibrosis,14,15 contributing to LV
diastolic dysfunction.16 We observed that preoperative LA
dilatation, reflecting the chronicity and diastolic dysfunc-
tion severity,17 is associated with greater LV hypertrophy
before and after surgery. In the present study, the LA diam-
eter did not decrease after AVR, even after LV reverse re-
modeling was completed. Previous studies have shown
that diastolic dysfunction can even worsen in the long
term after AVR,2 suggesting that diastolic dysfunction is
yet another enduring consequence of aortic stenosis, even
after successful AVR.
More severe aortic stenosiswas associatedwith decreased
LVEF and, after AVR, less complete LV reverse remodeling.
Although the focus is frequently on systolic dysfunction, it is
important to emphasize that a decrease in LVEF is a late sign
of disease progression, often a consequence of ischemia,
fibrosis, and coronary artery disease.18,19
Incomplete LV reverse remodeling has been linked to the
transprosthesis gradient after AVR, causing prosthesis–pa-
tient mismatch.20 We found only a modest effect of an ele-
vated postoperative transprosthesis gradient on residual
LV hypertrophy, a unique contribution of the present study.
The presence of preoperative LV hypertrophy and the LA di-
ameter are much stronger predictors of postoperative LV
recovery.
Preoperative LV hypertrophy can reflect other disease
processes, such as hypertension, that contribute to chronic
afterload elevation. Angiotensin-converting enzymeThe Journal of Thoracic and Cainhibitors have been shown to be safe in the context of
mild and moderate aortic stenosis.21 In the context of severe
aortic stenosis, the Symptomatic Cardiac Obstruction–Pilot
Study of Enalapril in Aortic Stenosis (SCOPE-AS) random-
ized trial has demonstrated that angiotensin-converting
enzyme inhibitors improve symptoms and exercise toler-
ance. However, in patients with heart failure and LV dys-
function without hypertension, an angiotensin-converting
enzyme inhibitor should not be used because hypotension
can ensue.22
Left Heart Remodeling: Symptoms
The current indications for surgery in patients with severe
aortic stenosis are heavily symptom based.3 However, their
presence can be difficult to ascertain and their absence
misleading.23,24 The use of exercise stress testing or the
6-minute walk test can augment the evaluation of these
patients. One third to two thirds of patients who report no
symptoms develop exercise-induced symptoms,25 and these
patients are more likely to develop spontaneous symptoms
earlier than those with negative test findings.
Consistent with others, we found that the degree of LV
hypertrophy and diastolic dysfunction were risk factors
formortality after AVR but correlated poorly with the symp-
tom severity.26 Symptom status was neither reflective of the
state of the myocardium nor the disease severity and should
not be the primary indication for surgical intervention.
Left Heart Remodeling: Survival
The importance of LV hypertrophy and LA size was fur-
ther underscored through their association with survival.
The known risk factors for mortality after AVR for aortic
stenosis include older age, greater functional class, severe
symptoms, and LV hypertrophy.1 We add the important
risk factor of LV diastolic dysfunction, as reflected by an
increased LA diameter. Compared with Mihaljevic and col-
leagues,1 our data have shown a relatively diminished effect
of LV hypertrophy on survival after updating the original
cohort, with more patients and longer follow-up and includ-
ing the LA diameter in the analysis. However, we noted an
impressive 34% decrease in 10-year survival in patients
with dilated left atria. Similar to LV hypertrophy, diastolic
dysfunction is not benign and has been identified as a predic-
tor of mortality before the development of symptoms27 and
late mortality after AVR in patients with aortic stenosis.2
The LA diameter is powerfully associated with long-term
survival and underscores the importance of assessing LV
diastolic dysfunction in preoperative decision making.
Strengths and Limitations
In the present single-institution observational study, we
had opportunistic, rather than systematic, echocardio-
graphic follow-up data available. We could not know
whether patients had follow-up TTEs available randomlyrdiovascular Surgery c Volume 147, Number 1 367
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Dor informatively. Because our institution is a referral center,
many patients are followed up entirely by their local cardi-
ologist. To address this, a subset of more than 1000 patients
with echocardiographic follow-up at the Cleveland Clinic
for longer than 6 months was analyzed, and the findings
were consistent with those of the overall groups
(Appendix E5). Despite these limitations, the number of
available postoperative echocardiograms was larger than
that of other known studies, and powerful longitudinal
data analysis techniques enabled incorporating multiple
measurements over time at disparate intervals instead of
using designated measurement points.12 To our knowledge,
only 1 study has used these techniques to examine the
changes in LV hypertrophy after AVR13; however, in con-
trast, we studied more patients and variables.
Another limitation not unique to our study was that our
primary predictor, LV hypertrophy, can be influenced by
common diseases not deeply investigated in the present
study, notably, systemic hypertension. Preoperative hyper-
tension was associated with increased preoperative LV hy-
pertrophy and incomplete LV reverse remodeling; however,
we did not have longitudinal postoperative blood pressure
data available to determine its time-varying influence on
LV reverse remodeling. We were also limited by the accu-
racy and variability of our echocardiographic measure-
ments over time and between observers. However, this
would blunt an effect rather than introduce a spurious
one. Additionally, we were restricted to the LA diameter
as a surrogate for diastolic dysfunction. However, the LA
diameter is nearly linearly correlated with the LVMI and,
as others have demonstrated, prognostically powerful.2,28
The indexed LA diameter was not as strong a risk factor
as the unindexed size.
However, many factors occurring after AVR also affect
survival, such as atrial and ventricular arrhythmia, progres-
sive degeneration of the prosthesis, stroke, and other
adverse valve-related and nonvalve-related outcomes. We
did not consider any of the postoperative events as
time-varying covariables in our modeling. Because the oc-
currence and timing of other events are not known preoper-
atively, their inclusion in analyses such as we have
performed is arguable.
CONCLUSIONS
LV hypertrophy and, more notably, diastolic dysfunction
are consequences of long-standing aortic stenosis and are
powerful predictors of long-term survival after AVR. The
LVmass and LA diameter are easily and routinely measured
and monitored echocardiographically, in contrast to symp-
toms, which can be unreliable and difficult to elicit,24,29
yet still represent the primary indication for treatment.3 We
have shown that patients can have advanced changes in the
absence of symptoms, underscoring the inadequacy of symp-
tom presence as the sole guideline for the timing of AVR.368 The Journal of Thoracic and Cardiovascular SurgThis indicates that the condition of the heart at surgery pow-
erfully influences patient outcomes. Our study adds to the
volume of data suggesting that symptoms alone should not
be used to determine the optimal timing of treatment in pa-
tients with aortic stenosis. The clinical challenge in asymp-
tomatic patients with severe aortic stenosis is to detect
deleterious left heart remodeling at the subclinical stage to
perform AVR before the occurrence of irreversible changes
that diminish the long-term benefit of surgery. Our data sug-
gest that an LA diameter greater than 4 cm in the context of
severe LV hypertrophy could be an indication for early AVR
in patients with severe aortic stenosis, even in the absence of
symptoms, if supported by an appropriate prospective study.
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DAPPENDIX E1. NONLINEAR MIXED-MODEL
REGRESSION AND SHAPING PARAMETERS FOR
TEMPORALTRENDS
In brief, this method accounts for the possibility of a vary-
ing influence of factors on the temporal rate of left ventric-
ular (LV) reverse remodeling during periods of early rapid
change versus late slow change (similar to nonproportional
hazards in a survival analysis). It does so by identifying
additive time phases, each having different shaping param-
eters.E3 Each data-driven phase has a sealing parameter that
is a function of risk factors. Because of the method’s
mathematical properties (orthogonality), the same set of
factors can be considered simultaneously in each temporal
phase.Temporal Trend of LV Mass Index
The LV mass index at time t was modeled as the follow-
ing mixed model:

LV Mass IndexðtÞ  120
40

¼ logðEðtÞþLðtÞÞþu;
where E

t
¼ 0:61
expfð0:008tÞ0:9gð0:008tÞ0:09, LðtÞ¼0:0296t,
and u is the patient-specific random effect (intercept). We
assumed a normal distribution for the random effects and
error.Temporal Trend of LV Ejection Fraction
The LVejection fraction at time twas modeled as the fol-
lowing mixed model:

LVEFðtÞ50
12

¼ logEtþCþu;
where E

t
¼ 0:004
expfð0:0001tÞ0:2gð0:0001tÞ1:2, C¼1:8859,
and u is the patient-specific random effect (intercept) with
distributional assumption as above.Temporal Trend of Left Atrial Diameter
The left atrial (LA) diameter at time twas modeled as the
following mixed model:

LA DiameterðtÞ
4:5

¼ logEtþCþLtþu;
where E

t
¼ 0:12
expfð4:87tÞ0:61gð4:87tÞ1:61, C ¼ 2:61,
LðtÞ ¼ 0:018t, and u is the patient-specific random
effect (intercept) with distributional assumption as
above.369.e1 The Journal of Thoracic and Cardiovascular SurgTemporal Trend of Aortic Valve Peak Gradient
Aortic valve (AV) peak gradient at time twas modeled as
the following mixed model:

AV Peak GradientðtÞ
25

¼ logEtþCþLtþu;
where E

t
¼ 0:98
expfð21:7tÞ2:4gð21:7tÞ3:4, C¼2:8,
LðtÞ¼0:40ð0:3tÞ0:35, and u is the patient-specific random
effect (intercept) with distributional assumption as above.APPENDIX E2. VARIABLES USED IN ANALYSES
Patient Data
Demographic data: Age (y), gender, weight (kg), height
(cm), body surface area (m2), bodymass index (kg/m2)
Symptoms: NewYork Heart Association functional class
(I-IV), emergency surgery
Aortic valveeryPhysiology: Aortic valve regurgitation, aortic valve
stenosis, orifice area (cm2), mean gradient (mm
Hg), peak gradient (mm Hg)
Etiology: Degenerative
Morphology: Calcification, thickened leaflets, fused
commissures, perforation, bicuspid valve
Other valvar pathology: Tricuspid valve regurgitation,
mitral valve regurgitation
Coronary anatomy: Left main trunk disease (percentage
of stenosis), left anterior descending coronary artery
system disease (maximum % stenosis), right coro-
nary artery system disease (maximum % stenosis),
left circumflex coronary artery system disease (max-
imum percentage of stenosis)
Ventricular dysfunction: Previous myocardial infarction,
degree of left ventricular dysfunction (1, none; 2,
mild; 3, moderate; 4, severe)
Left ventricle
Structure: Inner diameter in diastole (cm), inner di-
ameter in systole (cm), diastolic volume (mL),
systolic volume (mL), diastolic volume index
(mL/m2), systolic volume index (mL/m2), dilated
left ventricle
Function: Fractional shortening, ejection fraction (%),
relativewall thickness (wall stress), LV dysfunction
(grade: none, mild, mild to moderate, moderate,
moderate to severe, severe)
Mass: Mass (g), mass index (g/m2), posterior wall
thickness (cm), septal thickness (cm)
Left atrium: Left atrial diameter (cm), volume (cm3),
volume index (mL/m)c January 2014
Beach et al Acquired Cardiovascular DiseaseOther cardiovascular comorbidity: Preoperative atrial fi-
brillation, documented diagnosis of hypertension,
complete heart block requiring pacemaker, ventricu-
lar arrhythmia, ascending aortic aneurysm, peripheral
arterial disease, smoking, carotid disease, systolic and
diastolic blood pressure (mm Hg)
Noncardiac comorbidity: Treated diabetes, insulin-
treated diabetes, creatinine (mg/dL), blood urea nitro-
gen (mg/dL), bilirubin (mg/dL), creatinine clearance,
hematocrit (%)Intraoperative
Aortic valve prosthesis: Valve size (mm), in vitro effec-
tive orifice area (cm2), Z-value, Z-value for effective
orifice area, valve area/body surface area ratio
(cm2/m2), effective orifice area/body surface area
LV Mass IndexðtÞ  120
40

¼ fZ1b1þqLog

post op peak gradienttgþlogðexpðZ2b2ÞEðtÞþexpðZ3b3ÞLðtÞÞþu
A
C
Dratio (cm2/m2), internal valve area (cm2), effective
orifice area/internal area efficiency
Other procedure: Internal thoracic artery graft used, cor-
onary artery bypass grafting
Support: Aortic clamp time (min), cardiopulmonary
bypass time (min)
Experience: Date of operation (years since January 1,
1991)APPENDIX E3. BRIEF DESCRIPTION OF
METHODOLOGY TREATING AORTIC VALVE
GRADIENTAS ATIME-DEPENDENT
COVARIABLE
The outcome of interest was the temporal pattern of post-
operative left ventricular (LV) mass index after aortic valve
(AV) replacement, and we assessed the effect of the postop-
erative AV peak gradient on this temporal pattern. Thus, we
treated the postoperative AV peak gradient as a covariate
and assessed its influence on the longitudinal response,
postoperative LV mass index. However, the covariate, AV
peak gradient, unlike the baseline variables (eg, gender)
that were observed at AVR, changed with time. Thus, we as-
sessed the influence of a covariate that changed with time
and was observed after we started observing the longitudi-
nal response. Therefore, in this scenario, we treated the
postoperative AV peak gradient as a time-varying covariate.The Journal of Thoracic and CardIn the longitudinal data analysis, a time-varying covariate
can be considered as a covariate in a longitudinal model if
the covariate process satisfies the assumption of exogeneity.
A covariate process is exogenous with respect to an out-
come process if the covariate at time t is conditionally inde-
pendent of all preceding response measurements.
Thus, suppose Xit is the covariate value for patient i at
time t, HXi ðt1Þ is the history of the covariate process up
to time t  1, HYi ðtÞ is the response process up to time t,
and Zi is the baseline covariate, then the covariate process
is exogenous if, and only if,
f

Xit
HYi t;HXi t1; Zi ¼ f XitHXi t1; Zi:
Now, under this exogeneity assumption, we can include
the time-varying covariate postoperative gradient at time t
in the longitudinal model described in Appendix E1 as
follows:where Log is the natural logarithm and exp is the exponen-
tial function.APPENDIX E4. INFLUENCE OF DEMOGRAPHICS
ON LEFT VENTRICULAR REVERSE
REMODELING
Severe postoperative left ventricular (LV) hypertrophy
was more common in men and was not age dependent. It
was considerably less pronounced in younger women, but
increased with age (Figure E4, A). This relationship among
age, gender, and residual LV hypertrophy also existed pre-
operatively (Figure E4, B).
Younger patients with smaller left atria at surgery had
better survival than those with a larger diameter
(Figure E6). More symptomatic patients (New York Heart
Association functional class III or IV) experienced both
greater early mortality (30-day mortality, 50/2960 [1.7%]
vs 45/1304 [3.4%] for patients in New York Heart Associ-
ation I-II vs III-IV) and late mortality.
We observed significant gender differences in LV reverse
remodeling. More severe postoperative LV hypertrophy
was evident in elderly women. This finding was likely be-
cause women have a smaller aortic valve (AV) orifice
area, leading to an increased transvalvar gradient. These
findings are most notable in elderly women with ventriclesiovascular Surgery c Volume 147, Number 1 369.e2
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Dthat have been exposed to these conditions for longer. Such
women have been noted to have greater LV peak systolic
pressures and systolic function, possibly contributing to
the development of more LV hypertrophy compared with
men over time.E4,E5
The left atrial diameter is powerfully associated with
long-term survival, especially in younger patients, and un-
derscores the importance of assessing LV diastolic dysfunc-
tion in preoperative decision making.
APPENDIX E5. ANALYSIS OF
ECHOCARDIOGRAMS OF PATIENTS FOLLOWED
UP AT CLEVELAND CLINIC FOR MORE THAN 6
MONTHS
The number of available transthoracic echocardiograms
(TTEs) during follow-up decreased dramatically at the
same time as the greatest changes occurred in left heart re-
modeling (Figure 1 and Figures E1-E3). To address the
possibility that this was an artifact of TTE availability,
rather than a biologic phenomenon, we analyzed the
TTEs of patients with studies after 6 months or more of
follow-up at Cleveland Clinic, including all preoperative
studies for these patients before 6 months. Modes ofFIGURE E1. Number of patients with postoperative echocardiograms
available at and beyond various measurement points, number of echocar-
diograms available for analysis, and number of patients alive at each point.
369.e3 The Journal of Thoracic and Cardiovascular Surgincreased frequency of TTEs were present at yearly inter-
vals, most notably during the first 5 years (Figure E8).
This suggests substantial data from routinely scheduled
visits were available for analysis. The results of echocardio-
graphic analyses (Figure E9) mirror those presented in
Figure 1 and Figures E2 and E3.FIGURE E2. Left atrial (LA) diameter after aortic valve replacement (av-
erage preoperative value, 4.3 0.75 cm, normal 2.7-3.8 cm for women and
3.0-4.0 cm for men).E2 Solid line represents unadjusted estimate of tempo-
ral trend enclosed within 68% bootstrap percentile confidence limits. Red
circles represent data grouped (without regard to repeated measurements)
within time frames to provide crude verification of model fit.
ery c January 2014
FIGURE E3. Left ventricular (LV) ejection fraction after aortic valve re-
placement (average preoperative value, 52%  13%). Format same as in
Figure E2.
FIGURE E4. Relationship between age, gender, and left ventricular (LV)
hypertrophy. A, Nomogram of multivariate equation in Table 2, as de-
scribed in Figure 2. B, Relationship obtained by separate linear regression
for men and women. Red and blue dots represent data grouped (without re-
gard to repeated measurements) within time frames to provide crude veri-
fication of model fit.
FIGUREE5. Cumulative distribution of preoperative left ventricular (LV)
mass index, left atrial (LA) diameter, and LVejection fraction stratified by
New York Heart Association (NYHA) functional class. A, LV mass index.
B, LA diameter. C, LV ejection fraction.
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FIGURE E6. Relationship between age, preoperative left atrial (LA) di-
ameter (normal 2.7-3.8 cm for women and 3.0-4.0 cm for men),E2 and
10-year survival. Nomogram of multivariate equation given in Table E9.
Values for other risk factors were set as follows: smoker who underwent
surgery in January 2004, with tricuspid aortic valve, hypertension, periph-
eral arterial disease, left circumflex stenosis (>0%), and New York Heart
Association class I-II and without diabetes, renal disease, mitral regurgita-
tion, left main coronary artery stenosis (>70%), previous myocardial in-
farction, ventricular arrhythmia, or previous cardiac operation (body
mass index, 27 kg/m2; bilirubin, 0.65 g/dL; creatinine clearance, 65
mg/dL; blood urea nitrogen, 19 mg/dL; hematocrit, 38%; aortic orifice
area, 0.7 cm2; left ventricular mass index, 135 g/m2).
FIGURE E7. Relationship between postoperative left ventricular (LV)
mass index and survival in 2 hypothetical patients with otherwise identical
characteristics, except for postoperative LVmass index pattern. Nomogram
of univariate equation in Table E9. Each color represents patient-specific
LV mass index profile similar to 15th, 50th, and 85th percentiles, with re-
sultant survival in same color. Solid lines denote parametric estimates of
survival; dashed lines, postoperative LV mass index.
FIGURE E8. Number of patients with postoperative echocardiograms at
monthly postoperative intervals. Note, yearly increases in echocardio-
graphic measurements, suggestive of regularly scheduled follow-up exam-
inations.
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FIGUREE9. Temporal trends restricted to patients with 6months or more
of transthoracic echocardiographic (TTE) follow-up data, including all
available postoperative TTEs for these patients. Solid lines represent unad-
justed estimate of temporal trend enclosed within 68% bootstrap percentile
confidence limits. Red circles represent data grouped (without regard to re-
peated measurements) within time frames to provide crude verification of
model fit. A, Left ventricular (LV) reverse remodeling after aortic valve re-
placement. B, Left atrial (LA) diameter after aortic valve replacement. C,
Left ventricular (LV) ejection fraction after aortic valve replacement (aver-
age preoperative value, 52%  13%).
TABLE E2. Patient variables associated with larger preoperative
LVMI*
Variable Coefficient ± SE P value
Reliability
(%)y
Women 0.21  0.055 <.0001 81
Interaction (male 3
[age/50])
0.19  0.042 <.0001 91
Interaction (female 3
[age/50])
0.17  0.067 .005 91
Higher grade of aortic
regurgitation
0.042  0.0041 <.0001 100
Higher preoperative
AV peak gradientz
0.16  0.013 <.0001 100
Higher grade of mitral
regurgitation
0.015  0.0054 .005 99
Lower ejection fractionx 0.17  0.012 <.0001 100
Larger LA diameter{ 0.21  0.020 <.0001 100
Documented diagnosis of
hypertension
0.020  0.011 .05 72
Complete heart block/pacer 0.063  0.022 .004 95
Earlier date of surgery 0.016  0.0011 <.0001 100
LVMI, Left ventricular mass index; SE, standard error; AV, aortic valve; LA, left atrial.
*Logarithmic transformation of LVMI as response variable. yPercentage of times
factor appeared in 500 bootstrap analyses. zLn(AV peak gradient/28)2, squared trans-
formation. x(Ejection fraction/50)2, squared transformation. {(LA diameter/5)2,
squared transformation.
TABLE E1. Characteristics of aortic valve replacement (total
n ¼ 4264)
Procedure Details
Patients with
data available Value
Aortic prosthesis size (mm) 4264
19 607 (14)
21 1280 (30)
23 1525 (36)
25 695 (16)
27 143 (3.4)
29 14 (0.33)
Geometric prosthetic valve area (cm2) 4264 3.6  0.7
Normalized prosthetic valve area
(cm2/m2 BSA)
4264 1.8  0.33
Z-value* 4264 0.43  0.95
Coronary artery bypass grafting 4264 2332 (55)
Myocardial ischemic time (min) 4096 74  32
Cardiopulmonary bypass time (min) 4108 97  37
Data presented as n (%) or mean  standard deviation. BSA, Body surface area. *Pa-
tient–prosthesis size expressed as standardized orifice size (number of standard devi-
ations by which internal orifice diameter deviated from mean normal aortic annulus
diameter for patient BSA).E1
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TABLE E4. Patient variables associated with larger preoperative left
atrial (LA) diameter
Variable Coefficient ± SE P value
Reliability
(%)*
Older agey 0.13  0.025 <.0001 100
Larger BMI 0.0304  0.0021 <.0001 100
Higher grade of MV
regurgitationz
0.016  0.028 <.0001 100
Higher grade of TV
regurgitationx
0.012  0.028 <.0001 100
Larger LV mass index{ 0.52  0.043 <.0001 98
Larger LV systolic volumejj 0.045  0.0086 <.0001 81
Preoperative AF 0.37  0.051 <.0001 100
Preoperative ventricular
arrhythmia
0.15  0.038 <.0001 92
LAD system disease (70%
stenosis)
0.096  0.027 .0004 100
Previous cardiac surgery 0.21  0.032 <.0001 100
Peripheral arterial disease 0.061  0.025 .02 52
Higher BUN# 0.14  0.030 <.0001 100
Higher bilirubin** 0.075  0.024 .002 69
More recent date of surgery 0.011  0.0029 .0003 88
AF, Atrial fibrillation; BMI, body mass index; MV, mitral valve; TV, tricuspid valve;
LV, left ventricular; LAD, left anterior descending coronary artery; BUN, blood
urea nitrogen. *Percentage of times factor appeared in 500 bootstrap analyses.
y(Age/50)2, squared transformation. zLn(MV regurgitation þ 1), logarithmic trans-
formation. xLn(TV regurgitation þ 1), logarithmic transformation. {Ln(LV mass in-
dex), inverse transformation. jj(40/LV systolic volume), inverse transformation.
#Ln(BUN), logarithmic transformation. **Ln(bilirubin), logarithmic transformation.
TABLE E3. Preoperative risk factors associated with larger
postoperative LA diameter
Factor Coefficient ± SE
P
value
Overall
Larger preoperative LA diameter* 0.18  0.012 <.0001
Older agey 0.045  0.0202 .03
Larger BMIz 0.094  0.0098 <.0001
Tricuspid aortic valve 0.019  0.0062 .001
Higher LV systolic volumex 0.0027  0.001 .03
Larger septal thickness{ 0.014  0.0032 <.0001
Greater MV regurgitation 0.014  0.0059 .02
History of atrial fibrillation 0.069  0.011 .03
RCA stenosis (70%) 0.029  0.0056 <.0001
Higher bilirubink 0.021  0.0051 <.0001
Late phase
LMT stenosis (70%) 0.55  0.11 <.0001
LA, Left atrial; SE, standard error; BMI, body mass index; LV, left ventricular; MV,
mitral regurgitation; RCA, right coronary artery; LMT, left main trunk. *(LA diame-
ter/5)2, squared transformation. y(50/age), inverse transformation. z(1/BMI), inverse
transformation. x(LV systolic volume/40)2, squared transformation. {(Septal thick-
ness)2, squared transformation. kLog(bilirubin), logarithmic transformation.
TABLE E5. Preoperative risk factors associated with lower
postoperative LVEF
Factor Coefficient ± SE P value
Overall
Lower LVEF 0.036  0.0014 <.0001
Lower AV mean gradient 0.0042  0.00068 <.0001
Men 0.099  0.023 <.0001
Higher systolic volume index 0.013  0.0012 <.0001
Previous MI 0.12  0.025 <.0001
Previous cardiac surgery 0.061  0.028 .03
Lower systolic blood pressure 0.0018  0.00051 .0006
History of diabetes 0.065  0.026 .01
Higher BUN* 0.058  0.029 .05
Early phase
Older agey 0.64  0.29 .03
Greater diastolic blood pressurez 0.53  0.19 .008
Constant phase
Larger LA diameterx 0.15  0.048 .002
History of smoking 0.046  0.023 .05
LVEF, Left ventricular ejection fraction; SE, standard error; AV, aortic valve;MI,myo-
cardial infarction; BUN, blood urea nitrogen; LA, left atrial. *(20/BUN), inverse
transformation. y(50/age), inverse transformation. z(Diastolic blood pressure/75)2,
squared transformation. x(LA diameter/5)2, squared transformation.
TABLE E6. Patient variables associated with lower preoperative
LVEF
Variable Coefficient ± SE P value
Reliability
(%)*
Male gender 2.4  0.37 <.0001 98
Greater NYHA functional class 1.3  0.22 <.0001 99
Emergency surgery 13  3.9 .002 88
Smaller AVorifice areay 3.5  0.63 <.0001 100
Larger LV end-systolic volume
index
0.41  0.016 <.0001 100
Complete heart block/pacer 5.2  0.74 <.0001 100
LAD stenosis (>70%) 2.5  0.33 <.0001 99
Greater grade of mitral
regurgitation
1.2  0.21 <.0001 100
Greater grade of tricuspid
regurgitation
0.89  0.22 <.0001 100
Renal disease 2.1  0.79 .008 98
Greater BUN 0.065  0.018 .0003 98
Greater bilirubinz 1.2  0.36 .002 98
History of COPD 1.1  0.39 .007 55
LVEF, Left ventricular ejection fraction; SE, standard error; NYHA, New York Heart
Association; AV, aortic valve; LV, left ventricular; LAD, left anterior descending cor-
onary artery; BUN, blood urea nitrogen; COPD, chronic obstructive pulmonary dis-
ease. *Percentage of times factor appeared in 500 bootstrap analyses. yLog(AVarea),
logarithmic transformation. zLog(bilirubin), logarithmic transformation.
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TABLE E7. Preoperative variables associated with greater
postoperative AV peak gradient
Factor Coefficient ± SE P value
Overall
Greater AV mean gradient* 0.16  0.022 <.0001
Greater LV mass indexy 0.089  0.024 .0003
Greater LVEFz 0.049  0.0019 .01
Smaller AV prosthesis (Z-value) 0.18  0.0077 <.0001
Higher creatininex 0.0014  0.00069 .04
Absence of diabetes 0.053  0.016 .001
Late phase
Younger age{ 0.43  0.056 <.0001
Female 0.45  0.095 <.0001
Smaller BMIk 0.56  0.201 .005
Larger AVorifice area# 0.69  0.17 <.0001
Higher bilirubin** 0.201  0.079 .01
AV, Aortic valve; SE, standard error; LV, left ventricular; LVEF, left ventricular ejec-
tion fraction; BMI, body mass index. *Log(AV mean gradient), logarithmic transfor-
mation. yLog(LV mass index), logarithmic transformation. z(LVEF/50)2, squared
transformation. x(Creatinine)2, squared transformation. {Exp(age/50), exponential
transformation. kLog(BMI), logarithmic transformation. #(1/AV orifice area), loga-
rithmic transformation. **Log(bilirubin), logarithmic transformation.
TABLEE8. Effect of postoperative LVMI on death after AVR: focused
univariate analysis
Larger postoperative LV mass index Coefficient ± SE P value
Early hazard phase 0.053  0.29 .8
Late hazard phase 0.46  0.101 <.0001
LVMI, Left ventricular mass index; SE, standard error.
TABLE E9. Incremental risk factors for death after aortic valve
replacement: multivariate analysis
Factor Coefficient ± SE P value
Early hazard phase
Older age* 0.37  0.14 .009
Greater NYHA functional classy 0.75  0.18 <.0001
LMT disease (>70%) 0.56  0.28 .05
LCx disease (>0%) 0.47  0.22 .03
History of renal disease 0.93  0.30 .002
Lower creatinine clearancez 0.49  0.201 .01
Smaller prosthesis size
Z-valuex 0.18  0.097 .05
Postoperative LV mass index 0.12  0.27 .7
Late hazard phase
Older age* 0.64  0.081 <.0001
AV (native) orifice area{ 0.25  0.23 .3
Larger LV mass indexk
Interaction: LV mass index 3 AV
(native) orifice area#
LV dysfunction**
Previous MI
Ventricular arrhythmia 0.29  0.11 .009
Severe MV regurgitation gradeyy 0.36  0.15 .03
Lower hematocritzz 0.53  0.15 .0004
Greater BUN 0.014  0.0031 <.0001
Lower creatinine clearancez 0.24  0.099 .02
History of smoking 0.24  0.075 .001
Peripheral arterial disease 0.24  0.079 .002
Insulin-dependent diabetes 0.62  0.13 <.0001
Postoperative LV mass indexxx 0.094  0.13 .5
Larger LA diameter{{ 0.43  0.16 .008
Z-valuekk 0.28  0.074 .001
Interaction (Z-value 3 age)## 0.055  0.091 .004
SE, Standard error; NYHA, New York Heart Association; LMT, left main trunk; LCx,
left circumflex coronary artery; LV, left ventricular; AV, aortic valve; MI, myocardial
infarction;MV,mitral valve; BUN, blood urea nitrogen; LA, left atrial. *Exp(age/50),
exponential transformation. yNYHA class I/II vs III/IV (0/1), binary variable.
zLog(creatinine clearance), logarithmic transformation. xExp(Z-value), exponential
transformation. {(AV orifice area)2, squared transformation. k(LV mass index/
125)2, squared transformation. #Interaction: (AV orifice area)2 3 (LV mass index/
125)2. **LV dysfunction grades (none vs>none), binary variable. yy1/(MV regur-
gitationþ1], inverse transformation. zz(Hematocrit/40)2, squared transformation.
xxPostoperative LV mass index/120, scaled transformation. {{(LA diameter/5)2,
squared transformation. kk1/(Exponential transformation of Z-value), inverse trans-
formation. ##1/(Exponential transformation of Z-value)  exp(age/50).
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